Patent · US Active

Cysteine engineered antibodies and conjugates

US8309300B2 · kind B2 · utility

81Cited by

4References

6Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Jagath Reddy Junutula · Fremont, US
Henry B. Lowman · El Granada, US

Key dates

Filing date	Apr 21, 2009
Grant date	Nov 13, 2012
Priority date	—
Expiry date	Feb 15, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/624
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I:Ab-(L-D)p Iwhere p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.